Ani Pharmaceuticals (ANIP) Depreciation & Amortization (CF) (2010 - 2026)

Ani Pharmaceuticals has disclosed Depreciation & Amortization (CF) across 17 years of filings, most recently posting $19.6 million for Q2 2026.

• In Q2 2026, Depreciation & Amortization (CF) fell 15.64% year-over-year to $19.6 million; the TTM figure through Jun 2026 stood at $85.8 million (up 1.52% YoY), while the FY2025 annual figure was $91.4 million, up 34.97% from the prior year.
• Depreciation & Amortization (CF) came in at $19.6 million for Q2 2026 at Ani Pharmaceuticals, down from $20.9 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $23.3 million in Q2 2025 to a low of $13.8 million in Q2 2022.
• Average Depreciation & Amortization (CF) over 5 years is $17.6 million, with a median of $15.2 million recorded in 2023.
• Year-over-year, Depreciation & Amortization (CF) surged 58.41% in 2025 and declined 15.64% in 2026.
• Over 5 years, Depreciation & Amortization (CF) stood at $14.5 million in 2022, then rose by 4.9% to $15.2 million in 2023, then surged by 48.74% to $22.6 million in 2024, then increased by 0.06% to $22.6 million in 2025, then decreased by 13.15% to $19.6 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $19.6 million in Q2 2026, $20.9 million in Q1 2026, and $22.6 million in Q4 2025.